Andelyn, Purespring Partner to Advance Gene Therapies for Kidney Diseases

Andelyn Biosciences, Inc., a cell and gene therapy CDMO, has partnered with Purespring Therapeutics, a biotech innovator company, to accelerate the manufacture of their gene therapies for the treatment of chronic renal diseases.

Purespring will leverage Andelyn’s experience in adeno-associated virus (AAV) production and adapt Andelyn’s suspension platform to manufacture its preclinical and clinical gene therapy products under GMP. 

Matt Niloff, chief commercial officer of Andelyn, said, “Andelyn’s configurable AAV suspension platform is based on our vast database of historical data and decades of experience in viral vector development and quality manufacturing. We are honored to partner and serve as a key contributor to progress Purespring’s all-important kidney programs.”

Julian Hanak, CEO of Purespring, said, “Robust, high-quality manufacturing is absolutely critical to gene therapy. Purespring is excited to build on our longstanding working relationship with Andelyn to accelerate the pre-clinical and clinical manufacture of our innovative AAV-based gene therapies to help meet the unmet medical need of kidney disease patients worldwide.”